. 2021 Oct 15;11(5):544–563.

Table 1.

Summary of creation of comparison groups

Comparison groups’ summary

Studies	Basis of grouping	Groups	Total (n)	G-CSF (n)	Control/placebo (n)
Dallorso et al., 2002 [14]	Type of donor	MFD: Dallorso-A	53	23	30
Dallorso et al., 2002 [14]	Type of donor	MUD: Dallorso-B	38	20	18
Schriber et al., 1994 [17]	Type of GVHD prophylaxis	CSA/MTX/PSE: Schriber-A	44	17	27
Schriber et al., 1994 [17]	Type of GVHD prophylaxis	CSA/PSE: Schriber-B	38	13	25
Ringdén et al., 2004 [20]	Source of stem cells	BM: Ringden-A	1789	501	1288
Ringdén et al., 2004 [20]	Source of stem cells	PB: Ringden-B	434	175	259
Khoury et al., 2006 [21]	Type of donor and source of stem cells	HLA-identical sibling BM: Khoury-A	1435	282	1153
		HLA-identical sibling PB: Khoury-B	609	216	393
		Matched unrelated BM: Khoury-C	675	270	405
George et al., 2020 [23]	Type of donor	MFD: George-A	1487	313	1174
George et al., 2020 [23]	Type of donor	MUD: George-B	2075	417	1658

PB: Peripheral blood; BM: Bone marrow; MFD: Matched family donor; MUD: Matched unrelated donor; CDA: Cyclosporine; PSE: Prednisolone; MTX: Methotrexate.